Overview

Effect of Bile Acids on GLP-1 Secretion

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to describe the physiological, pathophysiological and potentially therapeutic implications of bile-induced glucagon-like peptide-1 (GLP-1) secretion in human glucose homeostasis.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Treatments:
Bile Acids and Salts
Chenodeoxycholic Acid
Colesevelam Hydrochloride
Criteria
Patients with type 2 diabetes

Inclusion Criteria:

- danish caucasian ethnicity

- normal haemoglobin

- BMI > 25 kg/m2

- HbA1c < 9%

- informed consent

Exclusion Criteria:

- liver disease(ALT and AST > upper reference limit)

- gastrointestinal disease

- liver and biliary tract disease

- nephropathy (serum creatinine > 150 μM, and/or albuminuria)

- treatment with insulin, glp-1 analogues and/ or DPP-4 inhibitors

- treatment with medicine that can not be paused for 12 hours

- previous abdominal surgery eg. cholecystectomy

- BMI < 18,5 kg/m2 or > 35 kg/m2

Healthy Volunteers

Inclusion Criteria:

- danish caucasian ethnicity

- normal haemoglobin

- HbA1c < 6,0 (American Diabetes Association guidelines)

- informed consent

Exclusion Criteria:

- liver disease(ALT and AST > upper reference limit)

- gastrointestinal disease

- liver and biliary tract disease

- nephropathy (serum creatinine > 150 μM, and/or albuminuria)

- treatment with medicine that can not be paused for 12 hours

- previous abdominal surgery eg. cholecystectomy

- BMI < 18,5 kg/m2 or > 35 kg/m2

- first degree relatives diagnosed with diabetes

- previously diagnosed with diabetes, or treated with antidiabetic agents